InvestorsHub Logo
Followers 4
Posts 388
Boards Moderated 0
Alias Born 10/28/2013

Re: couldbebetter post# 262751

Monday, 04/06/2020 2:14:12 AM

Monday, April 06, 2020 2:14:12 AM

Post# of 429287
JT claims Robust interest for Vascepa in Europe. Great! JT should
negotiate a BP BO mostly on the basis of Europe's value. BP can also
decide the best move regarding the generics. If BP owns AMRN they can
place the limited(?) supply of Vascpa to wherever it makes the most
economic sense. If the generics are not stopped, BP can concentrate
on Europe and the rest of the world.


This would be the easy way out but very stupid if you think the appeal has any chance of success. You would be giving them a 50-50 shot at billions for almost nothing!

If I wanted maximum value, I would sell EU to BP for cheap (say $1B with royalties but have them purchase a large stake in AMRN at a high valuation, maybe $10 a share buying 40% of the company).

That sets a "floor" for the share price and it also allows them a big vested interest to make the appeal succeed as well as support Vascepa's continued development (one pill combo etc).

They can have a separate gentleman's agreement to purchase AMRN outright based on success or failure of the appeal.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News